PH12022551937A1 - Compounds and uses thereof - Google Patents

Compounds and uses thereof

Info

Publication number
PH12022551937A1
PH12022551937A1 PH1/2022/551937A PH12022551937A PH12022551937A1 PH 12022551937 A1 PH12022551937 A1 PH 12022551937A1 PH 12022551937 A PH12022551937 A PH 12022551937A PH 12022551937 A1 PH12022551937 A1 PH 12022551937A1
Authority
PH
Philippines
Prior art keywords
compounds
treatment
present disclosure
related disorders
compounds useful
Prior art date
Application number
PH1/2022/551937A
Other languages
English (en)
Inventor
David S Huang
Rishi G Vaswani
Original Assignee
Foghorn Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Foghorn Therapeutics Inc filed Critical Foghorn Therapeutics Inc
Publication of PH12022551937A1 publication Critical patent/PH12022551937A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pyridine Compounds (AREA)
PH1/2022/551937A 2020-01-29 2021-01-29 Compounds and uses thereof PH12022551937A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202062967359P 2020-01-29 2020-01-29
PCT/US2021/015876 WO2021155262A1 (en) 2020-01-29 2021-01-29 Compounds and uses thereof

Publications (1)

Publication Number Publication Date
PH12022551937A1 true PH12022551937A1 (en) 2023-10-23

Family

ID=76970694

Family Applications (1)

Application Number Title Priority Date Filing Date
PH1/2022/551937A PH12022551937A1 (en) 2020-01-29 2021-01-29 Compounds and uses thereof

Country Status (17)

Country Link
US (3) US11485732B2 (cg-RX-API-DMAC7.html)
EP (1) EP4096664B1 (cg-RX-API-DMAC7.html)
JP (1) JP7561195B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220133258A (cg-RX-API-DMAC7.html)
CN (1) CN115023226A (cg-RX-API-DMAC7.html)
AR (1) AR121226A1 (cg-RX-API-DMAC7.html)
AU (1) AU2021213811A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022015004A2 (cg-RX-API-DMAC7.html)
CA (1) CA3167275A1 (cg-RX-API-DMAC7.html)
CO (1) CO2022010547A2 (cg-RX-API-DMAC7.html)
IL (1) IL295100A (cg-RX-API-DMAC7.html)
MX (1) MX2022009309A (cg-RX-API-DMAC7.html)
PH (1) PH12022551937A1 (cg-RX-API-DMAC7.html)
TW (1) TWI859406B (cg-RX-API-DMAC7.html)
UA (1) UA129728C2 (cg-RX-API-DMAC7.html)
WO (1) WO2021155262A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202207804B (cg-RX-API-DMAC7.html)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12282014B2 (en) 2015-11-19 2025-04-22 Dana-Farber Cancer Institute, Inc. Methods of identifying compounds that interfere with ERG-driven misguidance of BAF complexes in TMPRSS2-ERG driven prostate cancers
EP3746124A4 (en) 2018-01-30 2021-10-27 Foghorn Therapeutics Inc. COMPOUNDS AND THEIR USES
US12473334B2 (en) 2018-10-17 2025-11-18 Dana-Farber Cancer Institute, Inc. SWI/SNF family chromatin remodeling complexes and uses thereof
US12384776B2 (en) 2019-01-29 2025-08-12 Foghorn Therapeutics Inc. Compounds and uses thereof
US12509453B2 (en) 2019-01-29 2025-12-30 Foghorn Therapeutics Inc. BRM/BRG1 inhibitors and uses thereof
EP3917517A4 (en) 2019-01-29 2023-01-25 Foghorn Therapeutics Inc. CONNECTIONS AND USES THEREOF
WO2021155262A1 (en) 2020-01-29 2021-08-05 Foghorn Therapeutics Inc. Compounds and uses thereof
WO2021155264A1 (en) 2020-01-29 2021-08-05 Foghorn Therapeutics Inc. Compounds and uses thereof
WO2021236080A1 (en) * 2020-05-20 2021-11-25 Foghorn Therapeutics Inc. Methods of treating cancers
US12383555B2 (en) 2020-05-20 2025-08-12 Foghorn Therapeutics Inc. Methods of treating cancers
US12606553B2 (en) 2021-03-09 2026-04-21 Foghorn Therapeutics Inc. Crystalline forms, compositions containing same, and methods of their use
WO2022198043A1 (en) * 2021-03-19 2022-09-22 Foghorn Therapeutics Inc. Therapeutic regimens of an inhibitor of the enzymatic activity of brg1 and brm
US20240374605A1 (en) * 2021-07-29 2024-11-14 Foghorn Therapeutics Inc. Methods of treating cancer
WO2023196560A1 (en) * 2022-04-08 2023-10-12 Foghorn Therapeutics Inc. Methods of treating cancer
US20250339441A1 (en) * 2022-04-08 2025-11-06 Foghorn Therapeutics Inc. Methods of treating cancer
AU2023270055A1 (en) * 2022-05-11 2024-11-28 Foghorn Therapeutics Inc. Compounds and uses thereof
WO2024125543A1 (zh) * 2022-12-16 2024-06-20 苏州科睿思制药有限公司 达洛色替的晶型及其制备方法和用途
WO2024249769A2 (en) * 2023-06-02 2024-12-05 Foghorn Therapeutics Inc. Combination therapy for treating hematological cancers
IL326645A (en) * 2023-08-21 2026-04-01 Ideaya Biosciences Inc Pharmaceutical compositions comprising a pkc inhibitor
WO2025080769A1 (en) * 2023-10-10 2025-04-17 Foghorn Therapeutics Inc. Methods of treating cancer

Family Cites Families (157)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2788341A (en) 1953-03-06 1957-04-09 Ciba Pharm Prod Inc Process for the manufacture of aminoacyl compounds
US3624097A (en) 1969-07-22 1971-11-30 Warner Lambert Co N-pyridine 5-aminooxazoles
US4109496A (en) 1977-12-20 1978-08-29 Norris Industries Trapped key mechanism
FR2568880B1 (fr) 1984-08-07 1986-12-12 Synthelabo Derives d'acylaminomethyl-3 imidazo(1,2-a)pyridines, leur preparation et leur application en therapeutique
US4868103A (en) 1986-02-19 1989-09-19 Enzo Biochem, Inc. Analyte detection by means of energy transfer
US5080891A (en) 1987-08-03 1992-01-14 Ddi Pharmaceuticals, Inc. Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US6534055B1 (en) 1988-11-23 2003-03-18 Genetics Institute, Inc. Methods for selectively stimulating proliferation of T cells
US6352694B1 (en) 1994-06-03 2002-03-05 Genetics Institute, Inc. Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
US5858358A (en) 1992-04-07 1999-01-12 The United States Of America As Represented By The Secretary Of The Navy Methods for selectively stimulating proliferation of T cells
US6905680B2 (en) 1988-11-23 2005-06-14 Genetics Institute, Inc. Methods of treating HIV infected subjects
DE69210091T2 (de) 1991-05-31 1996-10-02 Sumitomo Pharma Leukotrien-B4-Antagonisten
EP0552108B1 (en) 1992-01-17 1999-11-10 Lakowicz, Joseph R. Energy transfer phase-modulation fluoro-immunoassay
JP3537141B2 (ja) 1992-10-30 2004-06-14 ザ ゼネラル ホスピタル コーポレーション 新種蛋白質分離のための相互作用を用いる補捉システム
US5656465A (en) 1994-05-04 1997-08-12 Therion Biologics Corporation Methods of in vivo gene delivery
US7175843B2 (en) 1994-06-03 2007-02-13 Genetics Institute, Llc Methods for selectively stimulating proliferation of T cells
US6692964B1 (en) 1995-05-04 2004-02-17 The United States Of America As Represented By The Secretary Of The Navy Methods for transfecting T cells
US7067318B2 (en) 1995-06-07 2006-06-27 The Regents Of The University Of Michigan Methods for transfecting T cells
US5677158A (en) 1995-06-07 1997-10-14 Research Foundation Of State University Of New York In vitro packaging of adeno-associated virus DNA
US5801030A (en) 1995-09-01 1998-09-01 Genvec, Inc. Methods and vectors for site-specific recombination
US6180612B1 (en) 1997-10-31 2001-01-30 The University Of Virginia Patent Foundation Methods and compositions for targeting DNA metabolic processes using aminoglycoside derivatives
US6683058B1 (en) 1998-04-15 2004-01-27 Regents Of The University Of California Methods for therapy of neurodegenerative disease of the brain
CA2329259C (en) 1998-05-27 2003-08-05 Avigen, Inc. Convection-enhanced delivery of aav vectors
JP2000095767A (ja) 1998-09-28 2000-04-04 Takeda Chem Ind Ltd 性腺刺激ホルモン放出ホルモン拮抗剤
WO2000024392A1 (en) 1998-10-26 2000-05-04 Sumitomo Pharmaceuticals Company, Limited β-AMYLOID FORMATION INHIBITORS
DE60014339T8 (de) 1999-04-02 2006-04-27 Neurogen Corp., Branford Aryl- und heteroaryl-kondensierte aminoalkyl-imidazol-derivate: selektive modulatoren der gabaa-rezeptoren
CA2369553A1 (en) 1999-04-02 2000-10-12 Raymond F. Horvath N-benzimidazolylmethyl and n-indolylmethyl-benzamides and their use as crf modulators
US7205103B2 (en) 2000-02-11 2007-04-17 The Salk Institute For Biological Studies Method of regulating transcription in a cell
US7572631B2 (en) 2000-02-24 2009-08-11 Invitrogen Corporation Activation and expansion of T cells
HK1052372A1 (zh) 2000-02-24 2003-09-11 Xcyte Therapies, Inc. 细胞的同步刺激和富集
US6797514B2 (en) 2000-02-24 2004-09-28 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
US6867041B2 (en) 2000-02-24 2005-03-15 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
EP1301214A2 (en) 2000-05-26 2003-04-16 Chiron Corporation Methods of transducing neural cells using lentivirus vectors
AU2001280576A1 (en) 2000-07-18 2002-01-30 Uab Research Foundation Tissue-specific self-inactivating gene therapy vector
WO2002020737A2 (en) 2000-09-07 2002-03-14 Vanderbilt University Genome engineering by cell-permeable dna site-specific recombinases
US6551786B2 (en) 2001-01-04 2003-04-22 Myriad Genetics, Inc. Screen assay for selecting protein-protein interaction modulators
JP2003033179A (ja) 2001-07-05 2003-02-04 Asahi Kasei Corp 可逆的遺伝子導入ベクター
JP2003077651A (ja) 2001-08-30 2003-03-14 Sharp Corp 有機エレクトロルミネッセンス素子の製造方法
EP1434579B1 (en) 2001-10-09 2011-06-08 Amgen Inc. Imidazole derivatives as antiinflammatory agents
US20050079512A1 (en) 2003-02-26 2005-04-14 Emerson Beverly M. Methods of modulating gene expression
WO2004078939A2 (en) 2003-03-03 2004-09-16 University Of Massachusetts REGULATION OF Mdm2 FUNCTION
US20050130919A1 (en) 2003-07-18 2005-06-16 University Of Massachusetts Regulatable promoters for synthesis of small hairpin RNA
AU2004283053A1 (en) 2003-10-20 2005-05-06 Nsgene A/S In vivo gene therapy of Parkinson's Disease
WO2005085443A2 (en) 2004-03-01 2005-09-15 Massachusetts Institute Of Technology Rnai-based therapeutics for allergic rhinitis and asthma
WO2005112620A2 (en) 2004-05-18 2005-12-01 Massachusetts Institute Of Technology A cre-lox based method for conditional rna interference
AU2005261487A1 (en) 2004-07-12 2006-01-19 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Amide derivatives as inhibitors of histone deacetylase
MX2007005611A (es) 2004-11-11 2007-07-11 Ferrer Int Compuestos de imidazo[1,2-a]piridina, composiciones, usos y metodos relacionados.
WO2006070806A1 (ja) 2004-12-28 2006-07-06 Taiho Pharmaceutical Co., Ltd. 新規ベンゾイミダゾール化合物及び該化合物を含有する医薬組成物
US20070105181A1 (en) 2005-05-04 2007-05-10 Invitrogen Corporation Identification of cancer biomarkers and phosphorylated pdroteins
BRPI0716583A2 (pt) 2006-08-24 2013-10-01 Australian Nuclear Science Tec ligandos fluorados para marcar recptores de benzodiazepina perifÉricos
US8324367B2 (en) 2006-11-03 2012-12-04 Medtronic, Inc. Compositions and methods for making therapies delivered by viral vectors reversible for safety and allele-specificity
PH12012502343A1 (en) 2007-05-23 2013-06-17 Siga Tech Inc Antiviral drugs for treatment or prevention of dengue infection
WO2008157500A1 (en) 2007-06-17 2008-12-24 Kalypsys, Inc. Aminoquinazoline cannabinoid receptor modulators for treatment of disease
AU2008345225A1 (en) 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms
CA2618163A1 (en) 2008-02-07 2009-08-07 K. W. Michael Siu Head and neck cancer biomarkers
CA2716947A1 (en) 2008-02-29 2009-09-11 Array Biopharma Inc. Imidazo [4,5-b] pyridine derivatives used as raf inhibitors
EP2349484A2 (en) 2008-07-15 2011-08-03 Novartis AG Heteroaryl derivatives as dgat1 inhibitors
CA2751412A1 (en) 2009-02-05 2010-08-12 Targeted Delivery Technologies Limited Methods of reducing the proliferation and viability of microbial agents
CN103038231B (zh) 2010-03-17 2016-04-20 泰纬生命科技股份有限公司 Hec1活性调节剂及其方法
EP2561351B1 (en) 2010-04-22 2015-12-09 British Columbia Cancer Agency Branch Novel biomarkers and targets for ovarian carcinoma
US20120035244A1 (en) 2010-07-29 2012-02-09 The Regents Of The University Of Michigan Parp1 targeted therapy
US9072052B2 (en) 2010-08-09 2015-06-30 Blackberry Limited Communication system providing context-based mobile wireless communications device power consumption management and related methods
US9656959B2 (en) 2010-12-22 2017-05-23 Purdue Pharma L.P. Substituted pyridines as sodium channel blockers
WO2012138789A2 (en) 2011-04-04 2012-10-11 Netherlands Cancer Institute Methods and compositions for predicting resistance to anticancer treatment
EP2697368B1 (en) 2011-04-15 2019-06-05 Genelux Corporation Clonal strains of attenuated vaccinia viruses and methods of use thereof
US8945861B2 (en) 2011-08-03 2015-02-03 Pierce Biotechnology, Inc. Methods for isotopically labeling biomolecules using mammalian cell-free extracts
US9403843B2 (en) 2012-02-01 2016-08-02 The Trustees Of Columbia University In The City Of New York Cysteine protease inhibitors and uses thereof
EP2809660B1 (en) 2012-02-02 2016-01-20 Ensemble Therapeutics Corporation Macrocyclic compounds for modulating il-17
ES2728782T3 (es) 2012-05-25 2019-10-28 Univ California Métodos y composiciones para la modificación de ADN objetivo dirigida por ARN y para la modulación de la transcripción dirigida por ARN
US8697359B1 (en) 2012-12-12 2014-04-15 The Broad Institute, Inc. CRISPR-Cas systems and methods for altering expression of gene products
CN105209621B (zh) 2012-12-12 2021-05-25 布罗德研究所有限公司 对用于序列操纵的改进的系统、方法和酶组合物进行的工程化和优化
KR102955556B1 (ko) 2012-12-12 2026-04-22 더 브로드 인스티튜트, 인코퍼레이티드 서열 조작을 위한 crispr-cas 성분 시스템, 방법 및 조성물
US9410943B2 (en) 2013-03-14 2016-08-09 The Board Of Trustees Of The Leland Stanford Junior University Methods, compositions and screens for therapeutics for the treatment of synovial sarcoma
ES2900301T3 (es) 2013-03-15 2022-03-16 Novartis Ag Biomarcadores asociados con la inhibición de BRM
EP2968318A4 (en) 2013-03-15 2016-12-14 Shifa Biomedical Corp ANTI-PCSK9 COMPOUNDS AND METHODS FOR TREATING AND / OR PREVENTING CARDIOVASCULAR DISEASES
US10976320B2 (en) 2013-05-21 2021-04-13 The Board Of Trustees Of The Leland Stanford Junior University Methods for identifying and treating cancer patients
JP6411342B2 (ja) 2013-07-03 2018-10-24 武田薬品工業株式会社 アミド化合物
US20160130663A1 (en) 2013-07-12 2016-05-12 National Cancer Center Method for predicting response to cancer treatment
EP3022197B1 (en) 2013-07-15 2017-09-06 Boehringer Ingelheim International GmbH Novel tetra- and pentasubstituted benzimidazolium compounds
WO2015046193A1 (ja) * 2013-09-25 2015-04-02 塩野義製薬株式会社 Trpv4阻害活性を有する芳香族複素環式アミン誘導体
US10266515B2 (en) 2013-12-30 2019-04-23 Lifesci Pharmaceuticals, Inc. Therapeutic inhibitory compounds
US9919998B2 (en) * 2014-02-06 2018-03-20 Rutgers, The State University Of New Jersey Antibacterial agents: Nα-aroyl-N-aryl-phenylalaninamides
GB201402771D0 (en) 2014-02-17 2014-04-02 Isis Innovation Biomarker & therapeutic target for sarcoma
EP3177640B1 (en) 2014-08-08 2020-05-06 The Board of Trustees of the Leland Stanford Junior University High affinity pd-1 agents and methods of use
WO2016054491A1 (en) 2014-10-03 2016-04-07 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US9636323B2 (en) 2014-10-27 2017-05-02 Baylor College Of Medicine Method of treating cancer that overexpresses TopBP1
CN104530013B (zh) 2014-12-04 2016-06-29 中国农业大学 基于吲哚环的吡唑酰胺类化合物作为农用杀菌剂的用途
US9546296B2 (en) 2014-12-15 2017-01-17 Ppg Industries Ohio, Inc. Coating compositions, coatings and methods for sound and vibration damping and water resistance
US9932340B2 (en) 2014-12-18 2018-04-03 Abbvie Inc. Substituted indoles
JP6815318B2 (ja) 2014-12-23 2021-01-20 ダナ−ファーバー キャンサー インスティテュート,インコーポレイテッド 二官能性分子によって標的化タンパク質分解を誘導する方法
US9694084B2 (en) 2014-12-23 2017-07-04 Dana-Farber Cancer Institute, Inc. Methods to induce targeted protein degradation through bifunctional molecules
MA41598A (fr) 2015-02-25 2018-01-02 Constellation Pharmaceuticals Inc Composés thérapeutiques de pyridazine et leurs utilisations
WO2016160718A1 (en) 2015-03-27 2016-10-06 University Of Washington Methods for treatment of retinal disease by photoreceptor gene expression modulation
US20180140722A1 (en) 2015-04-06 2018-05-24 The University Of North Carolina At Chapel Hill Methods and compositions for treatment of heart failure
EP3108883A1 (en) 2015-06-22 2016-12-28 Fundació Institut de Recerca Biomèdica de Bellvitge Therapeutic uses of non-peptide inhibitors of the calcineurin - nfat signalling pathway
WO2017007612A1 (en) 2015-07-07 2017-01-12 Dana-Farber Cancer Institute, Inc. Methods to induce targeted protein degradation through bifunctional molecules
CA2994969A1 (en) 2015-08-06 2017-02-09 Dana-Farber Cancer Institute, Inc. Targeted protein degradation to attenuate adoptive t-cell therapy associated adverse inflammatory responses
US20170100396A1 (en) 2015-10-07 2017-04-13 F. Hoffmann-La Roche Ag Pyrrolopyrazine derivatives for use in the treatment, amelioration or prevention of influenza
HUE067449T2 (hu) 2015-10-15 2024-10-28 Servier Lab Ivozidenib, citarabin és daunorubicin vagy idarubicin kombinációs terápa akut mielogén leukémia kezelésére
US12282014B2 (en) 2015-11-19 2025-04-22 Dana-Farber Cancer Institute, Inc. Methods of identifying compounds that interfere with ERG-driven misguidance of BAF complexes in TMPRSS2-ERG driven prostate cancers
US12233060B2 (en) 2016-01-08 2025-02-25 The Institute Of Cancer Research: Royal Cancer Hospital Inhibitors of Ataxia-Telangiectasia Mutated and Rad3-related protein kinase (ATR) for use in methods of treating cancer
CA3015753A1 (en) 2016-02-26 2017-08-31 Celgene Corporation Idh2 inhibitors for the treatment of haematological maligancies and solid tumours
WO2017150395A1 (ja) 2016-02-29 2017-09-08 フジテック株式会社 情報提供装置、エレベータの群管理システム、及びエレベータシステム
GB201604638D0 (en) 2016-03-18 2016-05-04 Mission Therapeutics Ltd Novel compounds
WO2017197046A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. C3-carbon linked glutarimide degronimers for target protein degradation
CN109562107A (zh) 2016-05-10 2019-04-02 C4医药公司 用于靶蛋白降解的杂环降解决定子体
CN109562113A (zh) 2016-05-10 2019-04-02 C4医药公司 用于靶蛋白降解的螺环降解决定子体
WO2018064589A1 (en) 2016-09-29 2018-04-05 Dana-Farber Cancer Institute, Inc. Targeted protein degradation using a mutant e3 ubiquitin ligase
US10207998B2 (en) 2016-09-29 2019-02-19 Duke University Substituted benzimidazole and substituted benzothiazole inhibitors of transforming growth factor-β kinase and methods of use thereof
US12023385B2 (en) 2017-02-08 2024-07-02 Dana-Farber Cancer Institute, Inc. Tunable endogenous protein degradation with heterobifunctional compounds
KR20190140438A (ko) * 2017-02-28 2019-12-19 에피자임, 인코포레이티드 암 치료를 위한 smarca2의 저해
EP3601326A4 (en) 2017-03-20 2020-12-16 The Broad Institute, Inc. COMPOUNDS AND METHODS OF REGULATING INSULIN SECRETION
WO2019040098A1 (en) 2017-08-21 2019-02-28 Dana-Farber Cancer Institute, Inc. METHODS OF MODULATING THE INTERACTION BETWEEN BAF COMPLEXES AND EWS-FLI1
KR20200043433A (ko) 2017-08-21 2020-04-27 메르크 파텐트 게엠베하 아데노신 수용체 길항제로서의 벤즈이미다졸 유도체
CN111601799B (zh) 2018-01-15 2023-06-09 Ucb生物制药有限责任公司 作为Il-17调节剂的稠合咪唑衍生物
EP3740482A1 (en) 2018-01-17 2020-11-25 Migal Galilee Research Institute Ltd. New methionine metabolic pathway inhibitors
CN112236172A (zh) 2018-01-30 2021-01-15 福宏治疗公司 用于治疗病症的方法和化合物
EP3746124A4 (en) 2018-01-30 2021-10-27 Foghorn Therapeutics Inc. COMPOUNDS AND THEIR USES
WO2019226915A1 (en) 2018-05-25 2019-11-28 Rutgers, The State University Of New Jersey Antibacterial agents: dual-targeted rna polymerase inhibitors
US20210260171A1 (en) 2018-06-21 2021-08-26 Foghorn Therapeutics Inc. Methods of treating disorders
WO2019246430A1 (en) 2018-06-21 2019-12-26 Foghorn Therapeutics Inc. Methods of treating disorders
CN112585136B (zh) 2018-08-17 2024-06-25 诺华股份有限公司 作为smarca2/brm atp酶抑制剂的脲化合物和组合物
US20210171958A1 (en) 2018-08-23 2021-06-10 Foghorn Therapeutics Inc. Methods of treating cancer
WO2020081556A2 (en) 2018-10-17 2020-04-23 Dana-Farber Cancer Institute, Inc. Non-canonical swi/snf complex and uses thereof
US12473334B2 (en) 2018-10-17 2025-11-18 Dana-Farber Cancer Institute, Inc. SWI/SNF family chromatin remodeling complexes and uses thereof
EP3883580A4 (en) 2018-11-21 2023-01-04 Foghorn Therapeutics Inc. Methods of treating cancers
MX2021006421A (es) 2018-12-19 2021-08-16 Leo Pharma As Anilidas de aminoácidos como moduladores de moléculas pequeñas de interleucinas-17 (il-17).
US12509453B2 (en) 2019-01-29 2025-12-30 Foghorn Therapeutics Inc. BRM/BRG1 inhibitors and uses thereof
AU2020214308A1 (en) * 2019-01-29 2021-08-12 Foghorn Therapeutics Inc. Compounds and uses thereof
US12384776B2 (en) 2019-01-29 2025-08-12 Foghorn Therapeutics Inc. Compounds and uses thereof
JP2022525149A (ja) 2019-03-20 2022-05-11 スミトモ ダイニッポン ファーマ オンコロジー, インコーポレイテッド ベネトクラクスが失敗した急性骨髄性白血病(aml)の処置
CA3150354A1 (en) 2019-09-12 2021-03-18 Muralidhara Ramachandra METHOD FOR IDENTIFYING RESPONDERS TO SMARCA2/4 DEGRADATION AGENTS
WO2021081032A1 (en) 2019-10-25 2021-04-29 Dana-Farber Cancer Institute, Inc. Compositions comprising modified smarcb1 and uses thereof
EA202192101A1 (ru) 2019-11-21 2021-12-09 Фогхорн Терапьютикс Инк. Соединения и их применение
WO2021155262A1 (en) 2020-01-29 2021-08-05 Foghorn Therapeutics Inc. Compounds and uses thereof
BR112022015110A2 (pt) 2020-01-29 2022-11-08 Foghorn Therapeutics Inc Compostos e usos dos mesmos
IL295176A (en) 2020-01-29 2022-09-01 Foghorn Therapeutics Inc compounds and their uses
WO2021155264A1 (en) 2020-01-29 2021-08-05 Foghorn Therapeutics Inc. Compounds and uses thereof
BR112022015109A2 (pt) 2020-01-29 2022-11-08 Foghorn Therapeutics Inc Compostos e usos dos mesmos
MX2022009308A (es) 2020-01-29 2022-08-22 Foghorn Therapeutics Inc Compuestos y usos de estos.
US20250283871A1 (en) 2020-03-13 2025-09-11 Dana-Farber Cancer Institute, Inc. Compositions and methods for modulating the interaction between ss18-ssx fusion oncoprotein and nucleosomes
WO2021236080A1 (en) 2020-05-20 2021-11-25 Foghorn Therapeutics Inc. Methods of treating cancers
US12383555B2 (en) 2020-05-20 2025-08-12 Foghorn Therapeutics Inc. Methods of treating cancers
US12606553B2 (en) 2021-03-09 2026-04-21 Foghorn Therapeutics Inc. Crystalline forms, compositions containing same, and methods of their use
WO2022192621A1 (en) 2021-03-12 2022-09-15 Celgene Corporation Methods for using a hypomethylating agent to treat diseases and disorders based on gene mutation profiles
WO2022198043A1 (en) 2021-03-19 2022-09-22 Foghorn Therapeutics Inc. Therapeutic regimens of an inhibitor of the enzymatic activity of brg1 and brm
US20240374605A1 (en) 2021-07-29 2024-11-14 Foghorn Therapeutics Inc. Methods of treating cancer
US20250339441A1 (en) 2022-04-08 2025-11-06 Foghorn Therapeutics Inc. Methods of treating cancer
WO2023196560A1 (en) 2022-04-08 2023-10-12 Foghorn Therapeutics Inc. Methods of treating cancer
WO2023196567A2 (en) 2022-04-08 2023-10-12 Foghorn Therapeutics Inc. Methods of treating a subject having clinically significant signs and symptoms associated with blood cell differentiation
CN218451564U (zh) 2022-08-09 2023-02-07 宁波立奇电器有限公司 一种双锅双风道式空气炸锅
WO2024086577A1 (en) 2022-10-17 2024-04-25 Foghorn Therapeutics Inc. Methods of reducing or preventing metastases
WO2024216151A1 (en) 2023-04-13 2024-10-17 Foghorn Therapeutics Inc. Combination therapy for treating hematological cancers
WO2024216136A1 (en) 2023-04-13 2024-10-17 Foghorn Therapeutics Inc. Combination therapy for the treatment of hematological cancers
WO2024249769A2 (en) 2023-06-02 2024-12-05 Foghorn Therapeutics Inc. Combination therapy for treating hematological cancers
WO2025080769A1 (en) 2023-10-10 2025-04-17 Foghorn Therapeutics Inc. Methods of treating cancer
WO2025080767A1 (en) 2023-10-10 2025-04-17 Foghorn Therapeutics Inc. Differentiation and maintenance dosing regimen for fhd 286 (brg1/brm inhibitor)

Also Published As

Publication number Publication date
US11485732B2 (en) 2022-11-01
BR112022015004A2 (pt) 2022-09-20
AR121226A1 (es) 2022-04-27
CO2022010547A2 (es) 2022-09-09
TW202136252A (zh) 2021-10-01
AU2021213811A1 (en) 2022-07-28
MX2022009309A (es) 2022-08-22
JP2023512039A (ja) 2023-03-23
TWI859406B (zh) 2024-10-21
IL295100A (en) 2022-09-01
JP7561195B2 (ja) 2024-10-03
CN115023226A (zh) 2022-09-06
UA129728C2 (uk) 2025-07-16
ZA202207804B (en) 2023-12-20
KR20220133258A (ko) 2022-10-04
CA3167275A1 (en) 2021-08-05
EP4096664A4 (en) 2024-02-28
US12486262B2 (en) 2025-12-02
US20230129003A1 (en) 2023-04-27
WO2021155262A1 (en) 2021-08-05
US20240101550A1 (en) 2024-03-28
US20210230154A1 (en) 2021-07-29
EP4096664B1 (en) 2026-07-29
EP4096664A1 (en) 2022-12-07

Similar Documents

Publication Publication Date Title
MX2023005436A (es) Compuestos y usos de estos.
MX2022009369A (es) Compuestos y usos de estos.
MX2022009308A (es) Compuestos y usos de estos.
ZA202207804B (en) Compounds and uses thereof
ZA202208421B (en) Compounds and uses thereof
MX2022012474A (es) Compuestos y usos de estos.
MX2022009366A (es) Compuestos y usos de estos.
WO2021022163A3 (en) Compounds and uses thereof
MX2025003987A (es) Antagonistas de cinasa progenitora hematopoyetica 1 (hpk1) y sus usos
EP4295846A3 (en) Heteroarylaminopyrimidine amide autophagy inhibitors and methods of use thereof
MX2025004367A (es) Inhibidores de la autofagia de fenilaminopirimidina amida y metodos de uso de estos
EP4438117A3 (en) Tyk2 inhibitors and uses thereof
WO2022109396A8 (en) Compounds and uses thereof
EP3848370A3 (en) Tyk2 inhibitors and uses thereof
MX2025006196A (es) Inhibidores de la autofagia de la amida aminopirimidina y sus metodos de uso
CR20200520A (es) Compuestos heterocíclicos como inmunomoduladores
MX2023013912A (es) Metodos para inhibir ras.
EP4635568A3 (en) Compounds, salts thereof and methods for treatment of diseases
GEP20247593B (en) Compositions and methods of inhibiting masp-3 for the treatment of various diseases and disorders
WO2019090085A8 (en) Modulators of the integrated stress pathway
GEAP202215479A (en) Magl inhibitors
EP4327809A3 (en) Tyk2 inhibitors and uses thereof
MX2023009060A (es) Antagonistas de gpr84 y usos de estos.
MX2024001243A (es) Composiciones y metodos para el tratamiento de melanoma.
EA202192101A1 (ru) Соединения и их применение